Health Catalyst, Inc.
NASDAQ:HCATMedical - Healthcare Information Services
-$0.04 today
- Market cap
- $98.24M
- Beta
- 1.66
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$3.65
Volume 0.27M
Average 1.24M
HCAT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Health Catalyst, Inc.NASDAQ: HCAT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $9.67M fell 36.3% year over year, behind the -24.0% change in trailing-twelve-month research & development. Sequentially, it fell 2.4% from the prior quarter. Over 3 fiscal years it compounded at -13.0% a year.
Context
- Research & development amounted to 16.0% of revenue in FY2025, down 2.9 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -36.3% toward the trailing-twelve-month pace of -24.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 49.77M USD
- Year-over-year change
- -14.1%
- 4-year CAGR
- -5.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.77M | -14.1% |
| FY2024 | 2024-12-31 | 57.95M | -20.2% |
| FY2023 | 2023-12-31 | 72.63M | -4.0% |
| FY2022 | 2022-12-31 | 75.68M | +20.6% |
| FY2021 | 2021-12-31 | 62.73M | — |
Research & Development vs competitors
How HCAT compares with its peers on the latest reported figures
- HCAT's LTM Mar 2026 research & development of $44.26M is the 7th highest of the 11 companies compared; the peer median is $61.43M.
- Its year-over-year change of -24.0% is the 6th highest of 11, against a peer median of -22.7%.
- Research & development amounts to 14.6% of revenue for HCAT, versus a peer median of 166.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $94.52M | -28.3% | +10.0% | 843.7% | |
| LTM Mar 2026 | $91.32M | -20.8% | -13.4% | 131.9% | |
| LTM Mar 2026 | $79.09M | -33.8% | +0.5% | 473.0% | |
| LTM Mar 2026 | $76.25M | +21.5% | -5.1% | 550.2% | |
| LTM Mar 2026 | $62.37M | -24.6% | -10.1% | 27721.8% | |
| LTM Mar 2026 | $60.48M | +28.2% | +38.4% | 184.8% | |
| LTM Mar 2026 | $44.26M | -24.0% | -13.0% | 14.6% | |
| LTM Mar 2026 | $21.34M | -31.8% | -24.3% | 18.1% | |
| LTM Dec 2025 | $19.24M | -4.7% | -10.1% | 147.7% | |
| LTM Mar 2026 | $2.57M | -32.8% | -6.3% | 26.8% | |
| LTM Mar 2026 | $1.81M | +151.4% | +33.6% | 4.1% | |
| Peer median (excluding HCAT) | $61.43M | -22.7% | -5.7% | 166.3% | |
Competitors are the stored peer set for HCAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 241.93M | 276.24M | 295.94M | 306.58M | 311.14M |
| Cost of Revenue | 124.35M | 143.05M | 164.11M | 165.81M | 207M |
| Gross Profit | 117.57M | 133.19M | 131.83M | 140.78M | 104.13M |
| Gross Margin | 48.6% | 48.2% | 44.5% | 45.9% | 33.5% |
| Research & Development | 62.73M | 75.68M | 72.63M | 57.95M | 49.77M |
| Selling, General & Admin | 160.96M | 149.22M | 143.88M | 111.2M | 102.04M |
| Operating Expenses | 261.22M | 273.19M | 258.73M | 210.59M | 140.24M |
| Depreciation & Amortization | 41.11M | 51.53M | 42.22M | 41.43M | 50.5M |
| EBITDA | (101.68M) | (82.92M) | (68.28M) | (10.65M) | (110.35M) |
| EBITDA Margin | -42.0% | -30.0% | -23.1% | -3.5% | -35.5% |
| Operating Income | (143.65M) | (140.01M) | (126.9M) | (69.81M) | (36.1M) |
| Operating Margin | -59.4% | -50.7% | -42.9% | -22.8% | -11.6% |
| Interest Income | 831K | 5.69M | 16.39M | 17.98M | 7.54M |
| Interest Expense | 17.31M | 7.24M | 7.29M | 17.09M | 16.4M |
| Other Income / Expenses | (16.46M) | (1.68M) | 9.11M | 637K | (141.15M) |
| Income Before Tax | (160.11M) | (141.68M) | (117.79M) | (69.17M) | (177.26M) |
| Pre-Tax Margin | -66.2% | -51.3% | -39.8% | -22.6% | -57.0% |
| Income Tax Expense | (6.9M) | (4.28M) | 356K | 333K | 716K |
| Net Income | (153.21M) | (137.4M) | (118.15M) | (69.5M) | (177.97M) |
| Net Margin | -63.3% | -49.7% | -39.9% | -22.7% | -57.2% |
| EPS (Basic) | (3.23) | (2.56) | (2.09) | (1.15) | (2.55) |
| EPS (Diluted) | (3.23) | (2.54) | (2.09) | (1.15) | (2.55) |
| Weighted Avg Shares | 47.49M | 53.72M | 56.42M | 60.19M | 69.9M |
| Weighted Avg Shares (Diluted) | 47.49M | 54.08M | 56.42M | 60.19M | 69.9M |
Health Catalyst, Inc.
NASDAQ:HCAT
Intrinsic Alpha fair value
Locked
Current Price
$1.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.